Interferon α2b Gene Delivery Using Adenoviral Vector Causes Inhibition of Tumor Growth in Xenograft Models from a Variety of Cancers

Cancer Gene Therapy volume 8, pages 788–795 (2001)

Posted: 17 Apr 2019

Date Written: October 12, 2001

Abstract

A recombinant adenovirus expressing human interferon α2b driven by the cytomegalovirus promoter, IACB, was shown to produce and secrete biologically active protein in vitro and in vivo. Intravenous administration of IACB in Buffalo rats resulted in circulating levels of biologically active human interferon at 70,000 international units/mL for up to 15 days. Distribution of interferon protein after IACB administration was different from that seen with the subcutaneous delivery of interferon protein. Higher levels of interferon protein were observed in liver and spleen after IACB delivery compared to protein delivery. The antitumor efficacy of IACB, as measured by suppression of tumor growth, was tested in athymic nude mice bearing established human tumor xenografts from different types of human cancer. Subcutaneous tumors most responsive to the intratumoral administration of IACB ranked as U87MG (glioblastoma) and K562 (chronic myelogenous leukemia), followed by Hep 3B (hepatocellular carcinoma) and LN229 cells (glioblastoma). Intravenous administration of IACB in animals bearing U87MG or Hep 3B xenografts was also effective in suppressing tumor growth, although to a lesser extent than the intratumoral administration. IACB was also tested in a metastatic model in beige/SCID mice generated with H69 (small cell lung carcinoma) cells and was found to prolong survival in tumor-bearing animals. This suggested that interferon gene delivery can be effective in suppressing tumor growth in a wide variety of cells.

Keywords: gene therapy, IACB, interferon α2b, glioblastoma, tumor suppression

Suggested Citation

Shinoda, Jeremy, Interferon α2b Gene Delivery Using Adenoviral Vector Causes Inhibition of Tumor Growth in Xenograft Models from a Variety of Cancers (October 12, 2001). Cancer Gene Therapy volume 8, pages 788–795 (2001). Available at SSRN: https://ssrn.com/abstract=3361763

Jeremy Shinoda (Contact Author)

Cordant Health Solutions ( email )

United States

HOME PAGE: http://www.cordantsolutions.com

Register to save articles to
your library

Register

Paper statistics

Abstract Views
28
PlumX Metrics